Key clinical point: Direct-acting oral anticoagulants appeared to be safer and more effective than warfarin in low-weight patients with atrial fibrillation.
Major finding: In low-weight patients, the composite adverse-event endpoint occurred in 34% fewer patients on a DOAC compared with warfarin.
Study details: Analysis of outcomes of 21,679 low-weight patients with AFib treated with an oral anticoagulant in the Korean National Health Insurance database.
Disclosures: Dr. Lee had no disclosures.
Lee SR et al. HRS 2019, Abstract S-AB30-05.